Earnings
Fonterra posts strong H2 2026, sees FY27 guidance hinge on stream returns
Fonterra reported FY26 return on capital above its 10%‑12% target, shares steady around $4.85, and said FY27 outlook depends on dairy stream return trends and shipping costs.
Elixirr AI Revenue Surges 185% as EBITDA Margin Tops 31% in H1 2026
Management consultant Elixirr reported H1 revenue of £89 million, up 25%, with adjusted EBITDA of £27.6 million. The London-listed firm saw AI-related income jump 185% year-over-year to roughly £8 million.
Elixirr H1 2026: AI revenue surges 185%, but valuation gap widens
London consultancy reports £89m revenue and strong AI growth, but says share price has not kept pace with sustained revenue outperformance versus the FTSE 100.
Protolabs Robotics Revenue More Than Doubles in First Half 2026
Minneapolis-based Protolabs says robotics-customer revenue more than doubled in H1 2026 versus the prior-year period, as the global robotics market is projected to grow at a 20% compound annual rate through 2031.
Stitch Fix Q4 Earnings Beat on EPS, Shares Fall on Weak FY2027 Guidance
Stitch Fix reported a Q4 EPS beat and record revenue per active client, but shares tumbled as the company guided for lower FY2027 revenue and significantly reduced EBITDA outlook.
Arq Highlights PFAS Initiative at Water Tower Research Virtual Conference
Arq discussed its PFAS strategy during the Water Tower Research Virtual Insights Conference, noting an improved outlook.
Novo Resources presents drill catalysts, value case at precious metals summit
Novo Resources outlined upcoming drilling milestones and its investment thesis at a recent precious metals conference.
Heritage Insurance at Small-Cap Virtual Conference: turnaround deepens
Heritage Insurance addressed its deepening turnaround at a small-cap virtual conference, according to an Investing.com earnings call transcript.
Huron Consulting at Sidoti Small-Cap Virtual Conference: Growth Stays Steady
Huron Consulting participated in the Sidoti small‑cap virtual conference and said its growth remains steady.
Alto Neuroscience Highlights Pramipexole-Ondansetron Combo for Treatment-Resistant Depression
Shares of ANRO fell 12% ahead of the TD Cowen summit where CEO Amit Etkin detailed the Phase IIb program ALTO-207 and its accelerated titration strategy for depression.
Rollins cites Google AI search shift for lead decline, maintains 6% organic growth guidance
Rollins Inc. told investors at the U.S. All Stars Conference that Google’s AI Overviews account for roughly half of its recent lead‑generation drop, but the pest‑control firm reaffirmed its full‑year 6% organic revenue growth target and a 10% incremental margin goal.
LB Pharmaceuticals Highlights lb-102 at TD Cowen Summit
LB Pharmaceuticals discussed its lb-102 candidate and its goal of safer psychiatric treatment at the TD Cowen summit.
Teamshares at Sidoti small-cap virtual conference: scaling a buy-and-build model
Teamshares discussed scaling its buy-and-build model at the Sidoti small-cap virtual conference.
Gevo highlights carbon stack at Water Tower conference
Gevo discussed its carbon stack and its positive impact on the company's outlook during the Water Tower Research Virtual Insights Conference.
ING Raises 2027 Profit Targets on Revenue Growth, Cost Cuts
Dutch bank upgrades return-on-equity target to above 16% and lifts 2027 revenue guidance by EUR 1 billion, citing momentum in retail lending, mortgages, and wealth management.
Rapport Therapeutics at TD Cowen summit: bipolar data loom
Rapport Therapeutics presented at the TD Cowen summit, where upcoming bipolar disorder data were discussed.
United Therapeutics at Bernstein forum: growth bets widen
United Therapeutics discussed broader growth initiatives at a Bernstein forum, according to the earnings call transcript.
Pyrum shares rise 15% after H1 2026 earnings, lifts output guidance
The Swiss recycler reported a 37.6% revenue jump to EUR 1.7 million, announced higher 2026 output targets and disclosed a new plant contract in the Czech Republic.
SThree Raises FY26 Profit Outlook Amid Q3 Revenue Recovery
Net fees fell 2% YoY in Q3 but improved sequentially, with U.S. and life sciences segments driving growth; share buyback and productivity gains support revised guidance.
Oruka reports strong week-28 psoriasis data for ORKA-001
Phase 2a EVERLAST-A trial showed 71.4% of patients achieved complete clearance (PASI 100) with ORKA-001, while safety remained favorable with no injection-site reactions reported.
Teva at Bank of America Global Healthcare Conference: growth takes center stage
Teva highlighted growth initiatives during its presentation at the Bank of America Global Healthcare Conference.
Peach Property Group Cuts Debt in Half, Beats Leverage Target on Track Early
The German-Swiss landlord reported a 25% rise in H1 adjusted EBITDA to EUR 30 million and cut total debt roughly in half, reaching its 2028 loan-to-value target two years ahead of schedule.
Agilent Technologies reports 10% Q3 organic growth, expands margins
The life‑science tools maker posted 10%‑11% organic growth in Q3, lifted operating margin by over 100 basis points and set Q4 growth guidance of 5.2%‑6.2%.
Peach Property cuts debt, halves vacancy rate in H1 2026 turnaround
Swiss-listed German landlord reports EUR 29.9m adjusted EBITDA, up 25%, as strategic portfolio shrinks to 80% of assets and LTV falls to 45.2%.
